Form D · Other
Neurexis Therapeutics, Inc.
Aurora, CO · CIK 0001849201
Offering snapshot reported May 23, 2022 · SEC filing
- Reported sold
- $55K Offering amount: $200K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 18, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 23, 2022 | Initial | $55,000 | No comparison | 1 | SEC filing |
| Apr 26, 2021 | Initial | $50,000 | No comparison | Not reported | SEC filing |
| Mar 4, 2021 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-446621
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed May 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Artinger | Director, Executive |
| Ulli Bayer | Director |
| Ulrich Bayer | Director |
| K. Ulrich Bayer | Director |
| Robert Calvin Goforth | Director |
Issuer details
Industry: Other (See others in industry)
Address:
12635 E Mountview Blvd. Suite 100
Aurora, CO, 80045
Aurora, CO, 80045